K E N R E S E A R C H China’s Insulin Market Is Becoming a Procurement-Scale Business: Ken Research Examines the Margin Test Behind 240+ Million Tendered Units Market Research Report September 23, 2026 www kenresearch com Table of Contents 1. Procurement Has Rewritten the Revenue Equation 2. Lower Prices Can Unlock Much Larger Volumes 3. The Patient Pool Is Huge , but Treatment Conversion Drives the Addressable Market 4. Analog Mix Is Improving Even as Tendering Caps Price 5. Product Mix Still Matters When List - Price Expansion Does Not 6. Competition Is Shifting From Brand Power to Tender Execution 7. Insulin Must Compete Within a Broader Metabolic - Care Portfolio 8. What Insulin Suppliers and Investors Should Watch Through 2032 9. Market Outlook : Volume Can Grow While Economics Stay Disciplined 10. Research Basis and Data Status 11. Research Framework China’s Insulin Market Is Becoming a Procurement-Scale Business: Ken Research Examines the Margin Test Behind 240+ Million Tendered Units China ʼ s insulin market is no longer best understood as a simple story of a growing diabetes population pushing medicine sales higher The newest complete insulin framework available from Ken Research places China at approximately USD 679 million in 2025 and cites a 7.3% external growth benchmark for the country The direction remains expansion , but centralized purchasing means future commercial value will depend as much on treatment volume , product mix and tender execution as on headline demand The underlying demand pool is exceptional China had approximately 148.0 million adults aged 20–79 living with diabetes in 2024 , according to the International Diabetes Federation Yet the market mechanism converting that disease burden into insulin revenue has changed : national volume - based procurement is lowering unit prices , expanding institutional access and altering which suppliers can capture large treatment volumes The counter - thesis is therefore important More patients and more insulin consumption do not automatically translate into equivalent revenue or margin growth when the public purchaser has substantial negotiating power The Asia - Pacific Insulin Market framework shows this tension clearly : volume expansion and formulation upgrading support demand , while public tendering — particularly in China — constrains price realization The market covered here includes human insulin and insulin analog formulations supplied through institutional , hospital , pharmacy and self - management channels ; it does not treat the wider diabetes - drug market as insulin revenue Procurement Has Rewritten the Revenue Equation China ʼ s national insulin procurement program has transformed purchasing power from a fragmented hospital - by - hospital mechanism into a market - shaping institutional channel The National Healthcare Security Administration reported that more than 35,000 medical institutions participated in the 2024 renewal and declared demand exceeding 240 million insulin units That scale gives successful suppliers access to exceptionally large volumes , but it also makes price , supply assurance and tender compliance central to commercial performance Lower Prices Can Unlock Much Larger Volumes The first national insulin procurement round reduced selected - product prices by an average of 48% The 2024 renewal then produced a further 3.8% reduction from the first - round selected - price level The important business implication is not simply that prices fell ; it is that China created a mechanism in which manufacturers can exchange lower realized prices for substantially greater institutional volume Scale matters more : production efficiency becomes critical when unit pricing is compressed Tender access becomes strategic : losing procurement eligibility can restrict access to a large portion of hospital demand Supply reliability gains value : public purchasers need manufacturers capable of meeting contracted volumes consistently Portfolio breadth becomes useful : companies able to compete across multiple insulin classes can participate in more clinical demand pools This logic overlaps with the Global Biosimilars Market , where competitive advantage increasingly depends on regulatory execution , scalable biologics manufacturing , reliable supply and payer access In China insulin , those capabilities are becoming commercial requirements rather than back - office strengths The Patient Pool Is Huge, but Treatment Conversion Drives the Addressable Market The International Diabetes Federation estimates that China had approximately 148.0 million adults aged 20–79 with diabetes in 2024 , the largest national total globally It also estimates that approximately 49.7% of adults with diabetes were undiagnosed That distinction matters commercially : disease prevalence describes potential need , while diagnosis , physician access , treatment initiation and therapy continuity determine actual medicine demand For insulin manufacturers , therefore , the most durable volume opportunity comes from expanding the treated population rather than relying on price inflation Screening , earlier diagnosis and broader chronic - care access can increase the number of patients entering formal treatment pathways This can create substantial physical - volume growth even if procurement prevents a comparable increase in average selling prices The long - term demand base also remains structurally large IDF projects China ʼ s adult diabetes population to reach approximately 168.3 million by 2050 That projection should not be interpreted as an insulin - sales forecast because not every person with diabetes requires insulin , but it shows why China will remain strategically important to manufacturers across metabolic medicines , monitoring and delivery technologies Analog Mix Is Improving Even as Tendering Caps Price Procurement has not produced a simple shift toward the cheapest possible therapy NHSA reported that third - generation insulin ʼ s share of usage increased from approximately 58% before the national procurement program to about 70% afterward This suggests that affordability improvements can coexist with clinical migration toward newer insulin formulations when the tender architecture preserves product choice and reduces the price gap between generations Product Mix Still Matters When List-Price Expansion Does Not This creates a more nuanced revenue model A supplier cannot depend on broad price increases , yet formulation mix can still influence revenue quality Basal and rapid - acting analogs , premixed analogs , convenient pen formats and next - generation dosing approaches can differentiate portfolios around adherence , simplicity and clinical positioning rather than price alone Technology around the molecule matters as well The Global Diabetes Devices Market provides adjacent context for the growing importance of glucose monitoring , insulin delivery and connected diabetes - management tools For insulin companies , pens , dosing simplicity , compatibility with monitoring workflows and patient adherence can increasingly support differentiation when the molecule itself faces procurement pressure Competition Is Shifting From Brand Power to Tender Execution China ʼ s insulin market has historically included major multinational suppliers such as Novo Nordisk , Eli Lilly and Sanofi alongside domestic producers including Gan & Lee Pharmaceuticals and Tonghua Dongbao Pharmaceutical The competitive question is now less about whether a company has a recognized insulin brand and more about whether it can combine portfolio depth , competitive bidding , manufacturing economics and dependable national supply A National Healthcare Security Administration review published in 2026 described the three major foreign insulin manufacturers as historically accounting for about 70% of the Chinese market before centralized procurement materially altered competitive dynamics NHSA also highlighted increased procurement volumes for domestic suppliers , illustrating how purchasing reform can accelerate share redistribution without eliminating multinational participation The 2024 renewal reinforces the competitive breadth of the system NHSA reported that 53 products from 13 companies entered the renewal process and 49 products secured selection status , a 92% selection rate That architecture can support multiple suppliers , but it places pressure on companies to demonstrate both price competitiveness and supply resilience Insulin Must Compete Within a Broader Metabolic-Care Portfolio Another constraint is therapeutic rather than procurement - driven Insulin remains indispensable for people whose clinical needs require it , but parts of the type 2 diabetes population can be managed or intensified with expanding classes of non - insulin medicines For pharmaceutical companies with broad metabolic portfolios , capital allocation therefore increasingly spans insulin , incretin - based therapies , oral medicines and combination approaches rather than treating insulin as an isolated franchise This does not eliminate insulin growth It changes where suppliers should expect it to come from Earlier diagnosis , initiation among undertreated patients , better treatment continuity and upgraded formulations can support expansion , while therapeutic substitution may moderate insulin use in eligible patient cohorts Companies need patient - level and channel - level demand models rather than assuming that overall diabetes prevalence translates proportionately into insulin consumption What Insulin Suppliers and Investors Should Watch Through 2032 The strongest indicators are increasingly operational Market growth will depend not just on how many people have diabetes , but on how procurement , product mix and treatment pathways convert need into profitable and sustainable supply Procurement demand : future declared volumes will show whether institutional insulin use continues expanding after the 2024 renewal Analog mix : movement beyond the current approximately 70% third - generation usage level would indicate continued upgrading of treatment mix Realized pricing : further tender compression would raise the importance of manufacturing cost , capacity utilization and procurement scale Domestic competitive gains : changes in contract volumes among Chinese manufacturers will show whether procurement continues redistributing the market Diagnosis conversion : with approximately 49.7% of adults with diabetes estimated to be undiagnosed in 2024 , screening and treatment initiation remain important volume variables Delivery innovation : adoption of easier dosing and connected diabetes - management tools could strengthen adherence and support differentiated portfolios Supply performance : manufacturers must demonstrate that aggressive tender prices remain compatible with dependable national availability Market Outlook: Volume Can Grow While Economics Stay Disciplined The current Ken Research framework benchmarks China ʼ s insulin market at approximately USD 679 million in 2025 and cites a 7.3% external growth benchmark in its country comparison The accessible current framework supports an expansionary market direction through the broader 2025–2032 insulin forecast period , but it does not publish a new standalone China terminal value that can be verified from the public country page A mechanically derived endpoint is therefore not presented as a proprietary forecast The structural opportunity is still substantial China combines the world ʼ s largest adult diabetes population with enormous institutional purchasing capacity and growing use of advanced insulin formulations The upside case is stronger diagnosis , higher treatment initiation , sustained analog migration and volume growth sufficient to offset lower unit prices The downside case is deeper procurement compression , aggressive domestic competition , therapeutic substitution in eligible patients or tender strategies that sacrifice too much margin for volume For decision - makers , this makes China a scale - and - execution market The companies best positioned to capture incremental value will be those able to manufacture biologics efficiently , maintain broad clinically relevant portfolios , price intelligently for centralized procurement and deliver contracted supply without compromising quality or continuity Don ʼ t miss the next test behind 240+ million tendered units shift Ken Research continuously publishes new market intelligence , forecasts and industry analysis Add Ken Research as a Preferred Source on Google to discover more of our research when your next market question comes up Research Basis and Data Status The supplied China Insulin Market URL currently exposes an older country report with publication metadata from September 2014 To avoid mixing obsolete country values with newer data , this article uses the newest complete Ken Research insulin framework available publicly : the Asia - Pacific Insulin Market report published in September 2026 , with a 2025 base year and a 2025–2032 forecast period Its country comparison provides the USD 679 million China market anchor and the 7.3% external growth benchmark used here The regional research framework combines desk research on diabetes prevalence , procurement , reimbursement , manufacturer portfolios and biologics capacity with primary research involving endocrinologists , diabetologists , hospital pharmacy directors , commercial executives and procurement managers The published methodology reports 186 respondents across insulin value - chain segments , with country demand anchors cross - validated , manufacturer supply estimates reconciled and the volume - value bridge independently checked Research Framework Diabetes prevalence and treatment - demand review Insulin procurement and reimbursement mapping Manufacturer portfolio and competitive analysis Biologics manufacturing and access benchmarking Primary interviews across clinical , pharmacy , commercial and procurement stakeholders Country - demand cross - validation and volume - value reconciliation Market values and growth frameworks identified as Ken Research estimates are treated as proprietary research outputs Diabetes prevalence figures are separately attributed to the International Diabetes Federation , while national procurement volumes , price reductions , selection rates and policy outcomes are attributed to China ʼ s National Healthcare Security Administration Company and competitive observations are kept distinct from government statistics Explore the China Insulin Market report for detailed market coverage , segmentation , competitive context and supporting research assumptions kenresearch com